Please go to the PowerPak homepage
and select a course.
Acute Lymphoblastic Leukemia in Adolescent/Young Adult and Adult Populations: Pharmacists' Key Roles in Ensuring Best Practices
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Shire.
Megan May, PharmD, BCOP
Clinical Oncology Specialist
Baptist Health Lexington
Megan May, PharmD, BCOP, discloses that she has no relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.
The following reviewer, Ashley Glode, PharmD, BCOP, hereby states she has no relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.
Susanne Batesko, RN, BSN, Robin Soboti, R.Ph, and Susan R. Grady, MSN, RN-BC, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 2.0 hours (0.20 ceu)
Type of Activity: Application
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 120 minutes
March 30, 2018
March 30, 2019
This accredited activity has been designed for pharmacists.
HOW TO EARN CREDIT
During the period March 30, 2018 through March 30, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the post-test and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
To inform and educate pharmacists about ALL, its etiology, treatment and pharmacist driven strategies to optimize patient care and outcomes.
At the conclusion of this activity, the learner will be better able to:
- Develop appropriate induction regimens for the initial treatment of adolescents/young adults (AYA) and adults with acute lymphoblastic leukemia (ALL) on the basis of individual risk factors and prognostic criteria
- Apply correct strategies for the management of relapsed/refractory ALL in AYA and adult populations on the basis of individual patient- and disease-specific factors
- Identify the roles for new and emerging therapies and regimens used to treat ALL in AYA and adults
- Select pharmacist-driven interventions to manage adverse events and drug-drug interactions and to optimize patient adherence to high-intensity chemotherapy and tyrosine kinase inhibitor regimens for the treatment of ALL
UPDATE: March 19, 2019
CORRECTION of 6-mercaptopurine dosing for patients with a low activity level.
The dosing of 6-mercaptopurine for patient with a low activity level is incorrect as stated the Preventing Drug-related Problems Section, paragraph 3, last sentence. The correct dosing is as follows:
If a patient has a low activity level, then 10% of the original 6-mercaptopurine dose should be prescribed; otherwise, standard dosing may be initiated and adjusted on the basis of tolerability.
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer:
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC and Shire. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.